Healthy future for China’s drug market
Print Edition
China’s pharmaceutical market is slated to grow 17 percent year on year through 2020 and become the world’s second largest pharmaceutical market, a latest industry report said.
The value of China’s pharmaceutical retail market will jump to 1.9 trillion yuan (US$310 billion) from 600 billion yuan in 2012, McKinsey said in a report co-published with Elsevier Business Intelligence and BayHelix Group yesterday.
Hospitals, expected to be the main sales channel for drugs, will continue to contribute around 84 percent of overall sales by 2020. Chronic disease and demographic shifts will drive up healthcare spending, the report said.
Multinational drug firms are optimistic about the market’s long-term growth potential as 90 percent of the executives in the report said China is already a top five global strategic priority for their companies.
“Pharmaceutical companies need to formulate new strategies and new business models to capture the growth opportunity,” said Franck Le Deu, partner and leader of McKinsey’s Healthcare Practice in China.
Joshua Berlin, head of emerging markets at Elsevier Business Intelligence, sees more partnerships with local firms to emerge in the next few years which can help speed up developing new drugs for the domestic market.
But 84 percent of respondents cited the lack of reimbursement for innovative drugs as a major barrier for growth.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
